



24 August 2021

## **ASX ANNOUNCEMENT**

### **Receipt of \$1.8 Million R&D Tax Incentive Refund**

ImpediMed Limited (ASX:IPD) today announced the receipt of a \$1.8 million cash refund related to the R&D Tax Incentive.

The cash rebate is related to expenditure on eligible Australian and international R&D activities during the 2021 financial year.

The \$1.8 million is a reduction on the previous years \$2.6 million refund, reflecting a decrease in expenditure related to the PREVENT trial, which was finalised in the 2021 financial year.

The receipt of the rebate strengthens ImpediMed's cash balance, as the Company focuses on commercialising the SOZO connected digital health platform.

**Approved for release by the Managing Director and CEO, Mr Richard Carreon.**

## **Contact Details**

### **Investor relations Contact:**

Mike Bassett, ImpediMed

T: +61 407 431 432

E: [mbassett@impedimed.com](mailto:mbassett@impedimed.com)

### **About ImpediMed**

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit [www.impedimed.com](http://www.impedimed.com).

### **About SOZO Digital Health Platform**

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.